Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Outset Medical (OM) over the last 7 years, with Q4 2025 value amounting to $172.8 million.

  • Outset Medical's Cash & Equivalents rose 3933.91% to $172.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $172.8 million, marking a year-over-year increase of 3933.91%. This contributed to the annual value of $172.8 million for FY2025, which is 3933.91% up from last year.
  • According to the latest figures from Q4 2025, Outset Medical's Cash & Equivalents is $172.8 million, which was up 3933.91% from $182.0 million recorded in Q3 2025.
  • In the past 5 years, Outset Medical's Cash & Equivalents ranged from a high of $274.3 million in Q2 2021 and a low of $35.5 million during Q1 2024
  • For the 5-year period, Outset Medical's Cash & Equivalents averaged around $129.7 million, with its median value being $100.3 million (2022).
  • As far as peak fluctuations go, Outset Medical's Cash & Equivalents crashed by 8558.97% in 2023, and later surged by 44161.39% in 2025.
  • Outset Medical's Cash & Equivalents (Quarter) stood at $215.7 million in 2021, then plummeted by 64.51% to $76.5 million in 2022, then fell by 6.13% to $71.8 million in 2023, then skyrocketed by 72.63% to $124.0 million in 2024, then soared by 39.34% to $172.8 million in 2025.
  • Its Cash & Equivalents was $172.8 million in Q4 2025, compared to $182.0 million in Q3 2025 and $187.4 million in Q2 2025.